Because of the abundance of promising preclinical and early-phase clinical data, mutation-derived tumor antigens an exciting new class of targets in cancer immunotherapy.
Alex Rubinsteyn, PhD
Advertisement
Articles by Alex Rubinsteyn, PhD
Advertisement
Latest Updated Articles
- Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy
Published: December 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5
